Document is current

Article History

First Online: 25 June 2020

Compliance with Ethical Standards

:

: This study was funded by Jazz Pharmaceuticals. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound (also known as SKL-N05), maintains rights in 12 Asian markets, including Korea, China, and Japan.

: Yves Dauvilliers has received consultancy fees and/or honoraria and has been a speakers’ bureau member and/or an advisory board participant for UCB Pharma, Bioprojet, Theranexus, Flamel, Harmony Biosciences, Takeda, Idorsia, and Jazz Pharmaceuticals. Colin Shapiro has received research funding from the National Institutes of Health and the Canadian Institutes of Health Research and has served on the speakers’ bureau for Jazz Pharmaceuticals. Geert Mayer has received honoraria from the Paul Ehrlich Institute, Germany; has served on the speakers’ bureau for UCB Pharma, Sanofi, and Bioprojet; and is a board member of the International REM Sleep Behavior Study Group. Gert Jan Lammers has received consultancy fees and/or honoraria and has been a speakers’ bureau member and/or an advisory board participant for UCB Pharma, Bioprojet, Theranexus, and Jazz Pharmaceuticals. Helene Emsellem has received consultancy fees, honoraria, and/or has been a speakers’ bureau member and advisory board participant for Jazz Pharmaceuticals and Vanda Pharmaceuticals; has received research funding from Jazz Pharmaceuticals, Vanda Pharmaceuticals, Eisai, Flamel (Avadel), Balance Therapeutics, Merck & Co, NightBalance, Novartis, Philips Respironics, Idorsia Pharmaceuticals, and Harmony Biosciences; and is a board member of the National Sleep Foundation. Giuseppe Plazzi has participated in advisory boards for UCB, Bioprojet, and Jazz Pharmaceuticals. Dan Chen, Lawrence P. Carter, and Lawrence Lee are employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Jed Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals plc. Michael J. Thorpy has received research/grant support and consultancy and speakers’ bureau fees from Jazz Pharmaceuticals; research funding from Flamel; consultancy and speakers’ bureau fees from Merck & Co., Inc., and Cephalon, Inc. (now Teva Pharmaceutical Industries, Ltd); and consultancy fees from Harmony Biosciences.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.